YATHARTH HOSP & TRA C S L
YATHARTH · Hospitals · NSE
₹757
Current Market Price
Fair Value (DCF)
₹755
Margin of Safety
-0.3%
Updated 2d ago
YieldIQ Score
58/100
Piotroski F-Score
5/9
Economic Moat
Wide
Confidence
43%
ROE
—
Debt/Equity
0.02
WACC
11.1%
Market Cap
₹7,291 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
10.9%
Return on capital employed
EV / EBITDA
26.2×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
23.9×
EBIT covers interest
Current Ratio
10.12×
Short-term liquidity
Asset Turnover
0.51×
Revenue per ₹ of assets
Revenue CAGR (3Y)
30.0%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹756.65
Bear case
₹423.75
MoS -78.6%
Base case
₹754.65
MoS -0.3%
Bull case
₹873.28
MoS +13.4%
Ratio Trends
YATHARTH · last 4 annual periods
ROE
8.0%
ROCE
14.3%
Operating Margin
—
Debt / Equity
0.01×
PE
—
EV / EBITDA
—
Historical Financials
YATHARTH · Annual, last 4 years· amounts in ₹Cr unless noted
| Metric | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|
| Revenue | ₹401 Cr | ₹520 Cr | ₹178 Cr | ₹880 Cr | +30.0% |
| EBITDA | ₹112 Cr | ₹137 Cr | ₹196 Cr | ₹236 Cr | +28.1% |
| EBIT | — | — | ₹44.5 Cr | — | +0.0% |
| PAT | ₹44.2 Cr | ₹65.8 Cr | ₹38.3 Cr | ₹131 Cr | +43.5% |
| EPS (diluted) | — | — | ₹4.85 | — | +0.0% |
| CFO | ₹59.9 Cr | ₹63.8 Cr | ₹-3.1 Cr | ₹150 Cr | +35.7% |
| CapEx | ₹-13.1 Cr | ₹-19.8 Cr | — | ₹-311 Cr | — |
| FCF | ₹46.8 Cr | ₹44.0 Cr | — | ₹-161 Cr | — |
| Total Assets | ₹426 Cr | ₹486 Cr | ₹1019 Cr | ₹1731 Cr | +59.6% |
| Total Debt | ₹264 Cr | ₹267 Cr | ₹7.8 Cr | ₹11.6 Cr | -64.7% |
| Shareholders' Equity | ₹117 Cr | ₹183 Cr | ₹874 Cr | ₹1637 Cr | +141.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
YATHARTH vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| JLHL JLHL | — | — | Pending | 14.3% | — |
| HCG HCG | — | — | Pending | 4.5% | — |
| JSLL JEENA SIKHO LIFECARE LTD | -38.5% | 51 | Above Fair Value | 33.2% | — |
| NEPHROPLUS NEPHROPLUS | — | — | Pending | 11.5% | — |
| PARKHOSPS PARKHOSPS | — | — | Pending | 18.2% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for YATHARTH in the last 10 years.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. YATHARTH HOSP & TRA C S L (YATHARTH.NS) trades at 756.65 vs a model fair value of 754.65, a gap of -0.3%. Piotroski F-score: 5/9. Moat la...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of YATHARTH →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for YATHARTH →
Compare
Head-to-head with peers
Compare YATHARTH side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse YATHARTHNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.